: +91 7428578883  : info@scienxt.com

Editorial Policies


An author is deemed to have made a significant intellectual contribution to a published study if they have contributed significantly to the conception and design, the collection of data, the analysis and interpretation of data, the writing of the manuscript or its critical revision for significant intellectual content, and the giving of the version to be published. Each author should have contributed sufficiently to the project to accept accountability for the appropriate portions of the work’s content and to agree to be responsible for all aspects of the work, including ensuring that any concerns about the work’s accuracy or integrity are duly investigated and acknowledged.The basic receipt of funds, data collecting, or overall oversight of the study team is typically insufficient to claim authorship. Those who contributed but didn’t match the requirements for authorship should all be acknowledged. It is important to recognize the contribution of scientific writers as well as their funding. All authors must certify in writing to SCIENXT-Centre of Excellence Publishing any suggested changes to the authorship of previously submitted works.

Competing Interests

A Competing Interests section outlining any competing interests must be included in every paper that is submitted. The phrase “The authors have declared that no competing interests exist” should be used when there are no competing interests. Editors may request more details regarding conflicting interests. A competing interest must be disclosed by editors and reviewers or they will be disqualified from participating in the peer review process.


Editors and reviewers must maintain the confidentiality of the manuscripts. Except in instances of suspected malfeasance, SCIENXT Publishing will not divulge manuscripts to parties outside of SCIENXT Publishing.

Plagiarism and Copyright

Any manuscript that is submitted to a journal must be unique and cannot already be under review by another publication. Each article is checked by SCIENXT Publishing for plagiarism, and any instances of publication misconduct are taken seriously. The ICMJE’s stance on overlapping publications is supported by SCIENXT Publishing. Text from the authors’ prior writings that has been copied is not accepted. Abstracts of up to 400 words and posters displayed at or published alongside academic gatherings do not exclude a full article from peer review. It is appropriate to cite published abstracts.The number of conference proceedings that surpass the permitted limit and are citable should be made clear to authors. If authors of non-research papers affirm upon submission that permission has been received from the original publisher and cite the original piece, they may incorporate figures and tables that have previously been published in other journals. Self-citation that is excessive or inappropriate is strongly discouraged. The legal accuracy of authors’ papers is their responsibility. Legally, Scienxt Publishing must make sure that none of the information published in its magazines violates copyright or contains libelous or defamatory statements. Manuscripts with content that might be libelous or defamatory, or that violates copyright, will be rejected.

Corrections and retractions

The publication of an erratum or a retraction article will be used to correct errors in or retract published articles. The original article will not be changed except to include a prominent link to the erratum/retraction piece. In the unlikely occasion that content is deemed to violate specific rights or is libelous, we may be required to delete it from our site, and archive sites.

Registration and reporting of data

Scienxt Publishing supports programs aimed at enhancing data reporting and registration. The ICMJE website has a list of registries where clinical trials can be registered. Consult the ICMJE FAQs if you’re not sure if you need to register your trial. The last line of the abstract should contain the trial registration number (TRN) and date of registration. Additionally, SCIENXT Publishing urges authors to submit their systematic reviews to the appropriate registry (such as PROSPERO). If the authors have registered their systematic review, they should mention it in the abstract of the publication.The following checklists should be used by authors and reviewers: CONSORT for randomized controlled trials, PRISMA for systematic reviews, STROBE for observational studies, MOOSE for meta-analyses of observational studies, STARD for studies on diagnostic accuracy, RATS for qualitative studies, and EVAL for economic evaluations (CHEERS). Use of standardized gene nomenclature is recommended. Inquiries or requests for new gene symbols should be sent through email to hgnc@genenames.org. Human gene symbols and names can be found in the HUGO Gene Nomenclature Committee (HGNC) database.It is expected of authors using unpublished genetic data to follow the rules of the Fort Lauderdale and Toronto accords. Authors have an ethical and legal obligation to respect participants’ right to privacy and to protect their identify while creating databases with clinical data. At the time of participant recruitment for the trial, authors should get participants’ informed consent for publishing of the dataset, and they should indicate this in their cover letter. If informed consent wasn’t obtained, the authors must explain why and name the organization that was consulted while creating the dataset.When a manuscript is submitted to a SCIENXT Publishing journal, it is implied that all commonly repeatable materials described in the manuscript, along with all pertinent raw data, will be made freely available to any researcher who wants to use them for non-profit endeavors without jeopardizing participant privacy. A suitable database should be used to store atomic coordinates, protein sequences, and nucleotide sequences in order for the accession number to appear in the article after it is published. The sequence information must be published as a separate file along with the paper in computational research when it is not acceptable for databases to store the sequence information due to a lack of experimental validation.

Any software that is mentioned in the publication should be accessible to reviewers for testing while maintaining their anonymity. The ‘availability and requirements’ part of the document has to describe how the reviewers can access the program. The software must to be accessible via a website or added as an additional file to the document. Any scientist who wants to use the software application/tool for non-commercial reasons should have easy access to it if it is published, without any restrictions (such the requirement for a material transfer agreement).

Wordpress Social Share Plugin powered by Ultimatelysocial